LINDIS Biotech Presented Encouraging Data from High Risk-Non-Muscle-Invasive Bladder Cancer Patients Treated with Trifunctional Antibody CATUMAXOMAB at EMUC22 Written by Kai Schmitz on 14th November 2022. Posted in Client News. Previous Next